By Karen Blum
Las Vegas—Even when prescriptions for costly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are approved by insurers for the management of low-density lipoprotein (LDL) cholesterol, some patients have delayed starting them.